Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to compare efficacy of IMM01 plus Tiselizumab with physician's choice chemotherapy of bendamustine or gemcitabine in participants with PD-(L)1-refractory classical Hodgkin Lymphoma. The study will also assess the safety and tolerability of IMM01 plus Tiselizumab. The primary study hypotheses are that IMM01 plus Tiselizuma is superior to physician's choice chemotherapy with respect to progression-free survival (PFS) and overall survival (OS).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06465446
Study type Interventional
Source ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Contact
Status Not yet recruiting
Phase Phase 3
Start date June 2024
Completion date July 2029

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03233347 - Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma Phase 2
Active, not recruiting NCT03712202 - Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma Phase 2
Recruiting NCT05833984 - Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas Phase 1/Phase 2
Active, not recruiting NCT02758717 - Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma Phase 2
Active, not recruiting NCT01771107 - Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma Phase 1/Phase 2
Active, not recruiting NCT02166463 - Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma Phase 3
Completed NCT00654732 - Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma Phase 2
Active, not recruiting NCT04788043 - Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma Phase 2
Recruiting NCT05955105 - A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies Phase 1/Phase 2
Completed NCT06235047 - Liposomal Doxorubicin-containing Front-line Treatment in Elderly Patients With HL (HL-MVD)
Recruiting NCT06164275 - Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma Phase 2
Active, not recruiting NCT05179603 - A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205] Phase 2
Active, not recruiting NCT03907488 - Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma Phase 3
Not yet recruiting NCT05949931 - Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma Phase 2
Not yet recruiting NCT06377540 - MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma Phase 2
Active, not recruiting NCT03057795 - Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma Phase 2